Scholarlink

Background <p>HPV is the most common sexually transmitted infection worldwide, related to the vast majority of cervical cancers (CC). Prevention through vaccination against HPV is considered one of the most effective control measures for CC. Madagascar is one of the few countries where HPV vaccination has not yet been widely disstrivuted in the country as the national program just started in December 2025. This study aims to estimate the prevalence of HPV genotypes in rural Madagascar in order to support the planning of a national vaccine implementation strategy. </p> Methods <p>A cross-sectional study was conducted between 2021 and 2022 in the Boeny region of Madagascar, involving women 18 to 49 years old. Cervico-vaginal lavages were collected and analysed for the presence of HPV DNA, covering 21 HPV genotypes. The prevalence of each HPV genotype was calculated as proportions with 95% confidence intervals (CI95%).</p> Results <p>From a total of 927 women enrolled, 44.6% (<i>n</i> = 413, CI95%: 41.3, 47.8) tested positive for HPV. The most commonly detected high-risk genotypes were HPV52 8.3% (CI95%: 6.6, 10.3), HPV45 7.2% (CI95%: 5.6, 9.1), and HPV51 4.8% (CI95%: 3.5, 6.3). The prevalence of vaccine-target genotypes was 7.4% (CI95%: 5.8, 9.3), 10.8% (CI95%: 8.9, 13.0), and 29.3% (CI95%: 26.4, 32.4) for 2-valent, 4-valent, and 9-valent vaccines, respectively.</p> Conclusions <p>Our results suggest that for a vaccination strategy aimed at preventing CC in Boeny, adoption of the 9-valent vaccine would increase the impact of the program.</p> Clinical trial <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating genotypes of human papillomavirus in adult women of reproductive age from the Boeny region of Madagascar: a cross-sectional study to explore needs and opportunities for HPV vaccination in the country

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月28日

查看全文
  • Ekaterine Garsevanidze,
  • Irina Kislaya,
  • Jean-Marc Kutz,
  • Tahinamandranto Rasamoelina,
  • Sonya Ratefiarisoa,
  • Ravo Razafindrakoto,
  • Zaraniaina Tahiry Rasolojaona,
  • Nantenaina Mathieu Razafindralava,
  • Olivette Totofotsy,
  • Alexina Olivasoa Zafinimampera,
  • Tiana Randrianarisoa,
  • Myriam Lassmann,
  • Aaron Remkes,
  • André Brito,
  • Diavolana Koecher Andrianarimanana,
  • Rivo Solotiana Rakotomalala,
  • Zoly Rakotomalala,
  • Pia Rausche,
  • Jana Hey,
  • Sandrine McKay-Chopin,
  • Jürgen May,
  • Monika Hampl,
  • Valentina Marchese,
  • Tarik Gheit,
  • Rivo Andry Rakotoarivelo,
  • Daniela Fusco

摘要

Background

HPV is the most common sexually transmitted infection worldwide, related to the vast majority of cervical cancers (CC). Prevention through vaccination against HPV is considered one of the most effective control measures for CC. Madagascar is one of the few countries where HPV vaccination has not yet been widely disstrivuted in the country as the national program just started in December 2025. This study aims to estimate the prevalence of HPV genotypes in rural Madagascar in order to support the planning of a national vaccine implementation strategy.

Methods

A cross-sectional study was conducted between 2021 and 2022 in the Boeny region of Madagascar, involving women 18 to 49 years old. Cervico-vaginal lavages were collected and analysed for the presence of HPV DNA, covering 21 HPV genotypes. The prevalence of each HPV genotype was calculated as proportions with 95% confidence intervals (CI95%).

Results

From a total of 927 women enrolled, 44.6% (n = 413, CI95%: 41.3, 47.8) tested positive for HPV. The most commonly detected high-risk genotypes were HPV52 8.3% (CI95%: 6.6, 10.3), HPV45 7.2% (CI95%: 5.6, 9.1), and HPV51 4.8% (CI95%: 3.5, 6.3). The prevalence of vaccine-target genotypes was 7.4% (CI95%: 5.8, 9.3), 10.8% (CI95%: 8.9, 13.0), and 29.3% (CI95%: 26.4, 32.4) for 2-valent, 4-valent, and 9-valent vaccines, respectively.

Conclusions

Our results suggest that for a vaccination strategy aimed at preventing CC in Boeny, adoption of the 9-valent vaccine would increase the impact of the program.

Clinical trial

Not applicable.